For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…

For many people interested in living longer, the goal is simple: avoid the "Big Four" diseases of aging. At the top of that list is cancer. Modern science is moving away from just treating cancer after it appears and toward Rapamycin and cancer prevention as a way to stop the disease before it even starts.…

Rapamycin and Metabolic Effects: Blood Sugar, Cholesterol, and What to Monitor The pursuit of human longevity has transitioned from speculative "elixirs" to the rigorous science of geroprotection, with the mechanistic target of rapamycin (mTOR) pathway serving as a central hub. While Rapamycin is the most robust pharmacological intervention for extending lifespan in model organisms, its…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…

For decades, the search for a true "longevity pill" was considered more science fiction than science. However, the discovery of the mTOR pathway and its inhibition by a soil-derived molecule called rapamycin has shifted that perspective. While animal studies have long shown that rapamycin can extend lifespan by up to 60%, the question of whether…

Can a drug originally used in organ transplant medicine hold the key to preventing Alzheimer’s disease? As we move into 2025, Rapamycin has transitioned from a niche "longevity molecule" to a primary subject of intense clinical investigation for dementia. Rapamycin is an FDA-approved mTOR inhibitor that researchers believe may slow the biological processes of aging…

For decades, people living with ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) have waited for treatments that address more than just symptoms. Now, new research led by Dr. Avik Roy at the Simmaron Research Institute suggests that an unexpected molecule—rapamycin—might help restore the underlying biology that drives fatigue in many patients. Why Rapamycin? A Closer…

Emerging evidence suggests that Rapamycin — an mTOR inhibitor long used in clinical settings — may suppress core aging mechanisms by moderating cellular hyperfunction, delaying age-related diseases, and extending lifespan across species. This positions Rapamycin and its analogs as serious candidates for “anti-aging” interventions in humans. Background: Why mTOR and Cellular Hyperfunction Matter in Aging…

“New research suggests low-dose rapamycin may reduce DNA damage in aging immune cells, supporting healthier aging and potentially extending human healthspan.” Recent findings suggest that rapamycin, an mTOR-inhibiting compound with established geroprotective effects in animal models, may enhance DNA damage resilience in aging human immune cells. This mechanism provides a compelling biologic rationale for its…

From longevity communities to advanced clinical research, rapamycin is emerging as one of the most promising tools for supporting healthy aging in women. Today, both scientific discoveries and real-world experiences are shaping a hopeful new chapter in women’s health and longevity. A Growing Movement: Women Turning to Rapamycin What excites me most is not only…